RNA · NUCLEIC-ACID · Severe acute respiratory syndrome coronavirus 2
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14RNA shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Use COVID-19 as the disease frame, then confirm a stable protein accession before cross-source reuse.
Use COVID-19 as the disease frame, then confirm a stable protein accession before cross-source reuse.
RNA shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with COVID-19 because it currently carries late clinical support. Linked drugs include MOLNUPIRAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyRNA
Review this target as RNA.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats RNA as ChEMBL target CHEMBL5604041. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether RNA still has a stable protein naming contract across sources.
Jump to Protein ContextUse this block first when you need to confirm why COVID-19 is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | RNA |
| Target Type | NUCLEIC-ACID |
| Organism | Severe acute respiratory syndrome coronavirus 2 |
Reviewable protein naming and mapping context for this target snapshot.
Review this target as RNA.
Open Targets-ready disease context using the current target-indication evidence contract.
RNA shows late clinical disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.
Start review with COVID-19 because it currently carries late clinical support. Linked drugs include MOLNUPIRAVIR. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.